Nimbus Therapeutics and Charles River Laboratories International, Inc. have entered a multi-year strategic partnership aimed at advancing new programs in immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.   The companies will work to advance programs through discovery and preclinical development, leveraging Charles River’s initial hit identification through discovery optimization, including medicinal chemistry and pharmac...